Research from our group and others has demonstrated that the proline hydroxylase EglN2 is an estrogen-responsive gene that is highly expressed in ER+ breast cancer, including luminal A and B subtypes, and contributes to breast tumorigenesis (42, 43). This evidence concerns the gene EGLN2 and breast carcinoma.